VLP Production and Purification: A Platform Bioprocess Guide from Expression to Formulation

What Are Virus-Like Particles?

Virus-like particles (VLPs) are self-assembling protein nanostructures that mimic the morphology of native virions but lack viral genetic material, making them non-infectious and non-replicating. VLPs range from 25 to 200 nm in diameter and present viral surface antigens in their native conformation, triggering strong humoral and cellular immune responses without adjuvant in many cases.

VLP technology has produced some of the most successful vaccines in history. Gardasil 9 (Merck) generated over $48 billion in cumulative revenue by 2021, and the hepatitis B VLP vaccines (Engerix-B, Recombivax HB) have been administered to billions of people worldwide. Beyond vaccines, VLPs serve as scaffolds for drug delivery, gene therapy vectors, and diagnostic reagents.

VLPs fall into two structural classes:

• Non-enveloped VLPs consist of one or more capsid proteins that self-assemble into icosahedral or rod-shaped particles (e.g., HPV L1, norovirus VP1, HEV p239). These are structurally robust and tolerate a wide range of purification conditions.
• Enveloped VLPs incorporate a host-cell-derived lipid bilayer with embedded viral glycoproteins (e.g., influenza HA/NA, HIV Gag, SARS-CoV-2 spike). These are more fragile and require gentler purification to preserve membrane integrity.

Expression System Selection for VLP Production

Choosing the right expression system is the single most consequential decision in VLP bioprocess development. The system determines yield, post-translational modifications, particle assembly efficiency, and downstream complexity. Six expression platforms have demonstrated commercial or clinical-scale VLP production, each with distinct trade-offs.

Bacterial Systems (E. coli)

E. coli accounts for approximately 28% of all VLP production and offers the lowest cost per gram of product. Yields reach 50 to 250 mg/L in fed-batch culture, with some optimized processes reporting higher. The hepatitis E vaccine Hecolin (Xiamen Innovax) uses E. coli-produced VLPs of truncated HEV capsid protein p239, demonstrating regulatory acceptance of this platform.

Limitations include the absence of glycosylation, endotoxin contamination requiring dedicated clearance steps, and the frequent need for in vitro disassembly and reassembly to remove misfolded aggregates and encapsulated host nucleic acids. VLPs produced in E. coli may also require refolding when expressed as inclusion bodies.

Yeast Platforms

Saccharomyces cerevisiae and Pichia pastoris combine eukaryotic protein folding with microbial growth rates. Yeast-produced VLPs power the most commercially successful VLP vaccines: Gardasil 9 (HPV L1 in S. cerevisiae) and both Engerix-B and Recombivax HB (HBsAg in S. cerevisiae). Yields of 50 to 700 mg/L are achievable in optimized fed-batch processes, with P. pastoris offering 11 to 28-fold productivity improvements over batch culture.

Yeast provides N-linked glycosylation but with high-mannose structures that differ from mammalian glycans. Hyperglycosylation can reduce serum half-life and may mask surface epitopes.

Baculovirus-Insect Cell System (BEVS)

The baculovirus expression vector system in Sf9 or Sf21 insect cells is the most versatile platform for VLP production. BEVS drives expression from the very late polyhedrin (polh) and p10 promoters, typically yielding 10 to 50 mg/L for VLP targets. Cervarix (GSK) uses BEVS-produced HPV L1 VLPs, validating this platform for licensed vaccines.

BEVS supports both enveloped and non-enveloped VLPs and provides eukaryotic post-translational modifications including disulfide bond formation and simple N-glycosylation (paucimannose). Key challenges include contamination of the harvest with baculovirus particles (which must be cleared or inactivated), the need to optimize multiplicity of infection (MOI), cell concentration at infection (CCI), and time of harvest (TOH) for each target.

Mammalian Cells

HEK293 and CHO cells produce VLPs with the most authentic human-like post-translational modifications, making them the preferred platform for complex enveloped VLPs requiring accurate glycosylation (e.g., influenza, HIV Gag, SARS-CoV-2 spike VLPs). However, yields are significantly lower (0.02 to 10 mg/L), production timelines are longer, and media costs are 5 to 10-fold higher than insect cell culture.

Plant-Based Systems

Transient expression in Nicotiana benthamiana can produce VLPs within 4 to 7 days post-infiltration. Medicago (now acquired by Mitsubishi Tanabe) advanced plant-derived influenza VLPs to Phase 3 trials. While yields vary widely (4 to 2,380 pg per mg leaf tissue), plant systems offer advantages in rapid response to pandemic threats and reduced downstream costs due to lower host cell protein burdens.

Upstream Production: Bioreactor Culture and Optimization

Upstream VLP production follows the same bioreactor principles as recombinant protein manufacturing, but with additional complexity from particle self-assembly. The culture mode, induction strategy, and harvest timing directly affect both VLP yield and particle quality.

Culture Modes

Three culture modes are used for VLP production:

• Batch culture is the simplest approach with the lowest contamination risk. It is widely used for E. coli and yeast VLP production, though substrate limitation and metabolite accumulation cap cell density and VLP titer.
• Fed-batch culture extends the exponential growth phase and increases volumetric productivity. For yeast-produced rotavirus VLPs, fed-batch achieved 28.5-fold higher volumetric productivity and 11-fold higher specific productivity compared to batch. Fed-batch is the dominant mode for BEVS and mammalian VLP production.
• Perfusion culture maintains cells in log phase continuously, producing the highest VLP titers per unit time. HIV-1 Gag VLP production in perfusion mode demonstrated a 2.4-fold yield improvement over batch. However, contamination risk increases with extended culture duration, and regulatory pathways for continuous manufacturing of VLP vaccines remain limited.

BEVS-Specific Optimization

For baculovirus-insect cell VLP production, three parameters dominate yield:

• Cell concentration at infection (CCI): Typically 1 to 3 x 10⁶ cells/mL. Higher CCI reduces per-cell yield due to nutrient limitation (the "cell density effect").
• Multiplicity of infection (MOI): Low MOI (0.01 to 0.1 PFU/cell) delays peak expression but maximizes total yield by allowing amplification. High MOI (1 to 10) synchronizes infection and shortens harvest time.
• Time of harvest (TOH): Optimal at 72 to 120 hours post-infection, depending on the VLP target. Harvesting too early leaves unreleased VLPs inside cells. Harvesting too late causes cell lysis, releasing proteases that degrade VLPs and increasing host cell protein and DNA burden in the harvest.

Bioreactor Considerations

VLP production uses standard stirred-tank bioreactors at scales from 2 L bench-top to 2,000 L production. Critical parameters include dissolved oxygen (maintained at 30 to 50% air saturation to prevent protease induction), temperature (27 to 28 °C for insect cells, 37 °C for mammalian, 30 to 37 °C for E. coli depending on solubility requirements), pH (6.0 to 6.4 for Sf9, 7.0 to 7.2 for HEK293), and agitation rate (balancing oxygen transfer against shear sensitivity for enveloped VLPs).

Single-use bioreactors are increasingly adopted for VLP manufacturing, eliminating cleaning validation and cross-contamination risk between product campaigns.

Downstream Processing: Clarification to Capture

VLP downstream processing replaces the unscalable density-gradient ultracentrifugation that dominated early VLP purification with a platform of membrane filtration and chromatography. The key challenge is separating 25 to 200 nm VLPs from similarly-sized contaminants (baculovirus particles at 40 to 60 x 250 to 300 nm, exosomes at 30 to 150 nm, host cell vesicles) while preserving particle integrity.

Cell Removal and Clarification

For intracellular VLPs (most non-enveloped particles from E. coli or yeast), cell lysis precedes clarification. Lysis methods include mechanical homogenization (high-pressure, 800 to 1,200 bar), chemical lysis (detergent-based), or freeze-thaw. Enveloped VLPs that bud from the cell membrane are typically harvested from the culture supernatant without lysis.

Clarification uses depth filtration (cellulose/diatomaceous earth media, 50 to 200 L/m² capacity) or disc-stack centrifugation (5,000 to 12,000 x g). Nuclease treatment with Benzonase (25 to 50 U/mL, 2 to 4 hours at room temperature) is applied before or after clarification to digest host cell DNA, reducing the downstream DNA clearance burden.

Concentration by Tangential Flow Filtration

TFF with 300 to 500 kDa MWCO hollow-fiber or flat-sheet cassettes concentrates the clarified harvest 10 to 50-fold while passing smaller contaminant proteins and nucleic acid fragments into the permeate. Polyether sulfone (PES) membranes are preferred for VLP applications due to low protein binding. Typical operating conditions: 2 to 5 L/m²/min cross-flow rate, 0.3 to 0.7 bar transmembrane pressure.

For enveloped VLPs, TFF shear must be carefully controlled. Hollow-fiber cartridges with larger lumen diameters (0.5 to 1.0 mm) reduce shear-induced particle disruption.

Chromatographic Purification and Polishing

Modern VLP purification relies on two to three chromatography steps to achieve the purity levels required for clinical and commercial vaccines. Anion-exchange chromatography (AEX) has emerged as the dominant capture step, replacing ultracentrifugation with a 220-fold improvement in productivity.

Anion-Exchange Chromatography (AEX) Capture

Most VLPs carry a net negative surface charge at physiological pH, making AEX the natural capture modality. Strong anion exchangers (quaternary amine, Q ligand) are preferred for their pH-independent binding. VLPs bind at low ionic strength (25 to 50 mM NaCl in Tris or phosphate buffer, pH 7.0 to 8.0) and elute at 200 to 500 mM NaCl, depending on the particle surface charge density.

Membrane adsorbers and monolith columns offer advantages over packed-bed resins for VLP chromatography because VLPs access binding sites by convective flow rather than diffusion into pores. This eliminates the mass transfer limitations that reduce dynamic binding capacity for large particles in conventional beaded resins. AEX monoliths achieve 3 to 5 log DNA clearance in a single step.

Size-Exclusion Chromatography (SEC) Polishing

SEC separates VLPs from remaining host cell proteins, residual DNA, and unassembled subunit proteins based on hydrodynamic radius. Optimized SEC removes greater than 97% of host cell proteins and enriches VLP preparations approximately 60-fold in a single step. Sepharose 4 Fast Flow (34 μm particle size) or Capto Core 400 (a core-bead with an inert outer shell and active octylamine core that captures small impurities while excluding large VLPs) are commonly used.

Capto Core 400 operates in a unique flow-through mode where VLPs pass through unretained while smaller contaminants (less than 400 kDa) enter the bead core and are captured by multimodal (hydrophobic + anion exchange) interactions. This enables integration of concentration and polishing in a single step.

Alternative and Emerging Methods

• Multimodal chromatography combines ion exchange with hydrophobic or hydrogen-bonding interactions, improving selectivity for VLPs in complex feedstreams.
• PEG/ammonium sulfate precipitation followed by resuspension provides a low-cost, scalable initial capture (40 to 60% PEG 6000 or 150 mM ammonium sulfate).
• Heparin affinity chromatography captures VLPs displaying heparan sulfate-binding domains (e.g., HPV, AAV-related).
• Steric exclusion chromatography (SXC) uses PEG-induced crowding to selectively precipitate VLPs on a cellulose matrix, offering a gentle, scalable alternative for enveloped particles.

Analytical Characterization of VLPs

VLP characterization requires orthogonal methods spanning biophysical, biochemical, and functional assays. Unlike soluble proteins, VLPs are nanoparticle assemblies where identity depends on both protein composition and higher-order structure.

Critical distinction: SDS-PAGE and ELISA can confirm protein identity and antigenicity, but they cannot differentiate assembled VLPs from unassembled subunits or partially assembled intermediates. TEM, DLS, and SEC-MALS are essential to confirm that the purified product is actually particulate. A VLP preparation that is antigenically active by ELISA but shows no particles by TEM has failed the identity test.

Formulation and Stability

VLP formulation must preserve particle structure, antigen conformation, and immunogenicity through manufacturing, storage, and administration. Enveloped VLPs are particularly fragile, losing membrane integrity under shear stress, pH extremes (below 5.0 or above 9.0), and freeze-thaw cycles.

Stabilizers and Excipients

• Surfactants: Polysorbate 80 (0.01 to 0.05% w/v) or polysorbate 20 prevents surface adsorption and aggregation. Nonionic surfactants are preferred as they do not disrupt lipid envelopes.
• Cryoprotectants: Trehalose or sucrose (5 to 10% w/v) for lyophilized formulations. Trehalose offers a higher glass transition temperature (T_g' = -27 °C vs -32 °C for sucrose), enabling shorter primary drying cycles.
• Buffers: Histidine (pH 6.0 to 6.5) or phosphate (pH 7.0 to 7.4) at 10 to 50 mM. Histidine avoids the pH drop during freezing that occurs with sodium phosphate buffers.
• Osmolality: Maintain 280 to 320 mOsm/kg for injectable formulations.

Adjuvant Systems

While VLPs are inherently immunogenic due to their repetitive surface structure and size (optimal for dendritic cell uptake), many vaccine VLPs are formulated with adjuvants. Aluminum hydroxide (alum) adsorption is used in Gardasil and Engerix-B. Cervarix uses AS04 (alum + monophosphoryl lipid A). The adjuvant adsorption step must be validated to confirm that VLP particles remain intact after binding to the aluminum salt.

Storage and Shelf Life

Liquid VLP vaccines are typically stored at 2 to 8 °C with shelf lives of 24 to 36 months. Stability studies must evaluate particle size (DLS), antigenicity (ELISA), and potency at real-time, accelerated (25 °C / 60% RH), and stress conditions. Lyophilized VLP vaccines can achieve room-temperature stability, which is critical for distribution in regions without cold-chain infrastructure.

GMP Manufacturing and Scale-Up Challenges

Scaling VLP production from laboratory bench to GMP manufacturing introduces challenges in maintaining particle quality, process consistency, and regulatory compliance. The multi-component nature of VLPs (some requiring co-expression of two or more structural proteins) adds complexity beyond standard recombinant protein manufacturing.

Scale-Up Considerations by Platform

Regulatory Requirements

VLP vaccines follow the same regulatory framework as other biologics. Demonstration and maintenance of comparability between different lots and between small-scale and large-scale clinical trial materials is a regulatory requirement. Process modifications must be verified by comparability analysis, typically comparing particle size distribution, protein composition, antigenicity, and in vivo potency across at least 3 to 5 lots per scale.

Baculovirus Clearance

For BEVS-produced VLPs, clearance of baculovirus particles is a unique challenge because baculovirus (40 to 60 nm x 250 to 300 nm rod-shaped) overlaps in size with many VLPs. Strategies include low pH inactivation (pH 3.0, 1 hour), detergent treatment (0.5% Triton X-100), UV-C irradiation (254 nm), and chromatographic separation exploiting differences in surface charge between VLPs and baculovirus. Validated baculovirus clearance of at least 4 log is typically required.

Process Analytical Technology

PAT implementation for VLP manufacturing uses at-line DLS for real-time particle size monitoring, in-line UV spectroscopy for chromatography step yields, and rapid ELISA or SPR-based antigenicity assays. A recently demonstrated platform process integrates PAT with fed-batch cultivation and consecutive purification steps, enabling real-time quality monitoring and automated process control for clinical-grade VLP production.

Frequently Asked Questions

Related Tools

• TOI/MOI Optimizer — Calculate optimal MOI, PFU requirements, and baculovirus infection parameters for BEVS VLP production.
• TFF/Filtration Calculator — Size membranes, calculate diafiltration volumes, and determine TMP for VLP concentration and buffer exchange.
• Chromatography Calculator — Design AEX and SEC purification steps with column sizing, gradient optimization, and resin selection.

References

1. Nooraei S, Bahrulolum H, Hoseini ZS, et al. Virus-like particles: preparation, immunogenicity and their roles as nanovaccines and drug nanocarriers. Journal of Nanobiotechnology. 2021;19:59. doi:10.1186/s12951-021-00806-7
2. Fuenmayor J, Gòdia F, Cervera L. Production of virus-like particles for vaccines. New Biotechnology. 2017;39:174-180. doi:10.1016/j.nbt.2017.07.010
3. Hillebrandt N, Vormittag P, Bluthardt N, Dietrich A, Hubbuch J. Integrated process for capture and purification of virus-like particles: enhancing process performance by cross-flow filtration. Frontiers in Bioengineering and Biotechnology. 2020;8:489. doi:10.3389/fbioe.2020.00489
4. Zhang J, Chen C. Downstream purification strategies for virus-like particles: a systematic review of structure preservation, impurity control, and viral safety. Microorganisms. 2026;14(4):858. doi:10.3390/microorganisms14040858
5. Baukmann S, Hengelbrock A, Katsoutas K, Stitz J, Schmidt A, Strube J. Platform process for an autonomous production of virus-like particles. ACS Omega. 2025;10(5):4810-4825. doi:10.1021/acsomega.4c09694